NZ600121A
(en)
|
2001-11-13 |
2013-12-20 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
JP5054975B2
(ja)
|
2003-09-30 |
2012-10-24 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノ随伴ウイルス(aav)の同源系統群、配列、それらを含有するベクターおよびそれらの用途
|
JP5702519B2
(ja)
*
|
2005-04-07 |
2015-04-15 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Aavベクターの機能を上げる方法
|
ES2400235T3
(es)
|
2006-04-28 |
2013-04-08 |
The Trustees Of The University Of Pennsylvania |
Método de producción escalable de AAV
|
CN104087591A
(zh)
*
|
2006-06-19 |
2014-10-08 |
阿斯克肋匹奥生物制药公司 |
用于基因治疗的修饰的因子viii和因子ix基因和载体
|
EP3492596A1
(de)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav-vektorzusammensetzungen mit tyrosinmodifizierten kapsidproteinen und verfahren zu deren verwendung
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
CN102159713A
(zh)
|
2008-05-20 |
2011-08-17 |
Eos神经科学公司 |
用于递送光敏蛋白的载体和使用方法
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
CN102439157B
(zh)
*
|
2009-04-30 |
2015-09-16 |
宾夕法尼亚大学托管会 |
包含腺伴随病毒构建体的靶向传导气道细胞组合物
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
WO2011038187A1
(en)
|
2009-09-25 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
|
US20130023033A1
(en)
|
2010-03-29 |
2013-01-24 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
EP3444346B1
(de)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-basierte behandlung von cholesterinerkrankungen
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
EP2826860B1
(de)
*
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
Auf das ZNS abzielende AAV Vektoren und Verfahren zur Verwendung davon
|
EP2605798A1
(de)
|
2010-07-12 |
2013-06-26 |
Universidad Autònoma de Barcelona |
Gentherapiezusammensetzung für die behandlung von diabetes
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
WO2012057363A1
(ja)
*
|
2010-10-27 |
2012-05-03 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
EP2699688A1
(de)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
RS60207B1
(sr)
|
2011-04-22 |
2020-06-30 |
Univ California |
Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
ES2752191T3
(es)
|
2012-02-17 |
2020-04-03 |
Childrens Hospital Philadelphia |
Composiciones y métodos con vectores de AAV para la transferencia de genes a células, órganos y tejidos
|
IN2014DN08812A
(de)
|
2012-04-18 |
2015-05-22 |
Philadelphia Children Hospital |
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
ES2684222T3
(es)
|
2012-08-01 |
2018-10-01 |
Nationwide Children's Hospital |
Administración intratecal de virus adenoasociado 9 recombinante
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
WO2014052789A1
(en)
|
2012-09-28 |
2014-04-03 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
KR102346455B1
(ko)
|
2013-03-15 |
2022-01-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Mpsi 치료를 위한 조성물 및 방법
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
SG11201510757PA
(en)
*
|
2013-05-21 |
2016-01-28 |
Univ Florida |
Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer
|
US11136557B2
(en)
|
2013-05-31 |
2021-10-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
KR102380265B1
(ko)
*
|
2013-07-22 |
2022-03-29 |
더 칠드런스 호스피탈 오브 필라델피아 |
변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
|
EP3633041A3
(de)
|
2013-09-26 |
2020-07-29 |
University of Florida Research Foundation, Inc. |
Kombinatorische synthetische aav-capsid-bibliothek für zielgerichtete gentherapie
|
US20150098925A1
(en)
*
|
2013-10-07 |
2015-04-09 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
CN106232618A
(zh)
|
2013-10-11 |
2016-12-14 |
马萨诸塞眼科耳科诊所 |
预测祖先病毒序列的方法及其用途
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
PT3116900T
(pt)
|
2014-03-09 |
2020-10-08 |
Univ Pennsylvania |
Composições úteis no tratamento da deficiência de ornitina transcarbamilase (otc)
|
SG10201810150UA
(en)
|
2014-03-17 |
2018-12-28 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression in cone cells
|
US10280418B2
(en)
|
2014-03-18 |
2019-05-07 |
Univeristy Of Massachusetts |
RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
EP3919508A1
(de)
|
2014-04-25 |
2021-12-08 |
The Trustees of The University of Pennsylvania |
Ldlr-varianten und deren verwendung in zusammensetzungen zur verringerung des cholesterinspiegels
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
IL292951B1
(en)
*
|
2014-05-02 |
2024-06-01 |
Genzyme Corp |
AAV vectors for gene therapy in the central nervous system and retina
|
CN106470736B
(zh)
|
2014-05-13 |
2021-05-28 |
宾夕法尼亚州大学信托人 |
包括表达双抗体构建体的aav的组合物及其用途
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP3180022A4
(de)
*
|
2014-08-13 |
2019-02-20 |
The Children's Hospital of Philadelphia |
Verbesserte expressionskassette zur verpackung und expression von variantem faktor viii zur behandlung von hämostatischen erkrankungen
|
CA2960912A1
(en)
|
2014-09-16 |
2016-03-24 |
Universitat Autonoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
CA2966620A1
(en)
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
US10597660B2
(en)
|
2014-11-14 |
2020-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
KR20240063169A
(ko)
|
2014-11-21 |
2024-05-10 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
중추 신경계에 표적화된 aav 벡터
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
EP3233131A1
(de)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Gentherapie für juvenile neuronale ceroid-lipofuszinose
|
WO2016110518A1
(en)
|
2015-01-07 |
2016-07-14 |
Universitat Autònoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
AU2016226289B2
(en)
|
2015-03-02 |
2021-04-29 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
CN107635575A
(zh)
|
2015-03-10 |
2018-01-26 |
纽约市哥伦比亚大学理事会 |
重组glut1腺相关病毒载体构建体以及用于恢复glut1表达的相关方法
|
ES2860712T3
(es)
|
2015-03-24 |
2021-10-05 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
US10555994B2
(en)
*
|
2015-03-30 |
2020-02-11 |
Boehringer Ingelheim Animal Health USA Inc. |
PCV2 ORF2 carrier platform
|
WO2016176191A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
CA2985223A1
(en)
|
2015-05-07 |
2016-11-10 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
CN108138159A
(zh)
|
2015-06-23 |
2018-06-08 |
费城儿童医院 |
经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
US10738087B2
(en)
|
2015-07-30 |
2020-08-11 |
Massachusetts Eye And Ear Infirmary |
Ancestral virus sequences and uses thereof
|
JP7409773B2
(ja)
|
2015-07-31 |
2024-01-09 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
改変された細胞および治療の方法
|
JP6978407B2
(ja)
|
2015-08-06 |
2021-12-08 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Glp−1及び代謝性疾患を治療するための組成物におけるその使用
|
MX2018002339A
(es)
|
2015-08-25 |
2018-12-19 |
Univ Duke |
Composiciones y metodos de mejora de la especificidad en ingenieria genomica usando endonucleasas guiadas por arn.
|
AU2016315699B2
(en)
|
2015-08-31 |
2021-09-09 |
The Trustees Of The University Of Pennsylvania |
AAV-EPO for treating companion animals
|
WO2017053732A2
(en)
|
2015-09-24 |
2017-03-30 |
The Trustees Of The University Of Pennsylvania |
Composition and method for treating complement-mediated disease
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
US20200181644A1
(en)
*
|
2015-10-22 |
2020-06-11 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial aav3 capsid library
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
CA3002982A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
KR20180100304A
(ko)
|
2015-10-28 |
2018-09-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
유전자 요법을 위한 아데노-관련-바이러스 벡터의 척추강 내 투여
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
US11028372B2
(en)
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
US10889832B2
(en)
|
2015-12-11 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
KR20180097631A
(ko)
|
2015-12-11 |
2018-08-31 |
매사추세츠 아이 앤드 이어 인퍼머리 |
핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
|
JP7406783B2
(ja)
|
2015-12-14 |
2023-12-28 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
CN109069668B
(zh)
|
2015-12-14 |
2023-04-18 |
宾夕法尼亚州大学信托人 |
用于眼病的基因疗法
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
MA43968A
(fr)
|
2016-02-03 |
2018-12-12 |
Univ Pennsylvania |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
IL305449A
(en)
|
2016-04-15 |
2023-10-01 |
Univ Pennsylvania |
Gene therapy for the treatment of type II mucositis
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
CN109661470A
(zh)
*
|
2016-04-15 |
2019-04-19 |
宾夕法尼亚州大学信托人 |
新型aav8突变衣壳和含有其的组合物
|
JP7046828B2
(ja)
|
2016-04-15 |
2022-04-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
滲出型加齢性黄斑変性の治療のための組成物
|
WO2017184463A1
(en)
|
2016-04-17 |
2017-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3448874A4
(de)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
CN109476707B
(zh)
|
2016-05-13 |
2022-12-02 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
KR102392236B1
(ko)
|
2016-05-18 |
2022-05-03 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
WO2017218450A1
(en)
|
2016-06-13 |
2017-12-21 |
The University Of North Carolina At Chapel Hill |
Optimized cln1 genes and expression cassettes and their use
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
KR20230062878A
(ko)
|
2016-07-08 |
2023-05-09 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
IL305149A
(en)
*
|
2016-07-26 |
2023-10-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
JP7071332B2
(ja)
|
2016-07-29 |
2022-05-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異カプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
EP3518985A4
(de)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
Aavrh.10-varianten mit austrittsmöglichkeiten für wirtsantikörper und veränderten gewebe-targeting-eigenschaften
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
EP4338799A3
(de)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumorinfiltrierende lymphozyten und therapieverfahren
|
WO2018075798A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
JP7065852B2
(ja)
|
2016-12-01 |
2022-05-12 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
網膜変性疾患の処置のための医薬組成物
|
WO2018139634A1
(ja)
*
|
2017-01-30 |
2018-08-02 |
学校法人日本医科大学 |
アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体
|
WO2018152485A1
(en)
|
2017-02-20 |
2018-08-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
CA3114549A1
(en)
|
2017-02-21 |
2018-08-30 |
University Of Florida Research Foundation, Incorporated |
Modified aav capsid proteins and uses thereof
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
CA3052487A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Influenza vaccines based on aav vectors
|
SG11201907714UA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
US11564996B2
(en)
|
2017-03-01 |
2023-01-31 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
TW201903146A
(zh)
|
2017-04-14 |
2019-01-16 |
美商銳進科斯生物股份有限公司 |
使用由人類神經或膠細胞產生的重組人類艾杜糖醛酸鹽 (iduronate)-2-硫酸酯酶 (ids) 之黏多醣病ii之治療
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
CN110913866A
(zh)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
WO2018204803A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
CN108103082B
(zh)
*
|
2017-05-11 |
2021-07-13 |
北京锦篮基因科技有限公司 |
一种腺相关病毒介导的lcat基因表达载体及其用途
|
WO2018209205A1
(en)
|
2017-05-11 |
2018-11-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
EP3630986A4
(de)
|
2017-05-31 |
2021-08-11 |
The Trustees of The University of Pennsylvania |
Gentherapie zur behandlung von peroxisomalen erkrankungen
|
US11827898B2
(en)
|
2017-06-14 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
WO2019006418A2
(en)
*
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Aavを送達するための組成物および方法
|
KR20200042935A
(ko)
*
|
2017-08-25 |
2020-04-24 |
오비드 테라퓨틱스 인크. |
재조합 아데노-관련된 벡터들
|
BR112020003571A2
(pt)
|
2017-08-28 |
2020-08-25 |
The Regents Of The University Of California |
variantes capsidiais de vírus adenoassociado e métodos de uso das mesmas
|
UA127455C2
(uk)
|
2017-09-20 |
2023-08-30 |
4Д Молекьюлар Терапьютикс Інк. |
Капсид аденоасоційованого вірусу і спосіб його застосування
|
TWI835747B
(zh)
|
2017-09-22 |
2024-03-21 |
賓州大學委員會 |
用於治療黏多醣病 ii 型之基因治療
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症(als)の治療
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
WO2019079496A2
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
|
EP3697449A1
(de)
|
2017-10-18 |
2020-08-26 |
REGENXBIO Inc. |
Behandlung von augenkrankheiten und metastasierendem dickdarmkrebs mit menschlicher post-translational modifizierter vegf-falle
|
EP4219695A3
(de)
|
2017-11-27 |
2024-01-17 |
4D Molecular Therapeutics Inc. |
Kapside mit adeno-assoziierten virenvarianten und verwendung zur hemmung der angiogenese
|
KR20200104307A
(ko)
|
2017-11-30 |
2020-09-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
뮤코다당류증 iiia형에 대한 유전자 요법
|
EP3717652A4
(de)
|
2017-11-30 |
2021-11-24 |
The Trustees of the University of Pennsylvania |
Gentherapie für mucopolysaccharidose iiib
|
EP3727468A4
(de)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
Aav-vermittelte abgabe von therapeutischen antikörpern an das innenohr
|
US10806802B2
(en)
|
2018-01-18 |
2020-10-20 |
University Of Guelph |
Adeno-associated virus particle with mutated capsid and methods of use thereof
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
EP3755795A4
(de)
|
2018-02-19 |
2022-07-20 |
Homology Medicines, Inc. |
Adeno-assoziierte viruszusammensetzungen zur wiederherstellung der f8-genfunktion und verfahren zur verwendung davon
|
CA3091806A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
KR20210006327A
(ko)
*
|
2018-02-27 |
2021-01-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
|
US20210032660A1
(en)
*
|
2018-03-29 |
2021-02-04 |
Asklepios Biopharmaceutical, Inc. |
Liver tropic recombinant aav6 vectors that evade neutralization
|
BR112020020223A2
(pt)
|
2018-04-05 |
2021-01-19 |
Genethon |
Sorotipo de vírus adeno-associado híbrido recombinante entre aav9 e aavrh74 com tropismo pelo fígado reduzido
|
WO2019212922A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
WO2019212921A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Scalable clarification process for recombinant aav production
|
AU2019265663B2
(en)
|
2018-05-08 |
2024-06-13 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
WO2019222328A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
KR20210020100A
(ko)
|
2018-06-14 |
2021-02-23 |
리젠엑스바이오 인크. |
재조합 aav 생성을 위한 음이온 교환 크로마토그래피
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
CN112770812A
(zh)
|
2018-07-24 |
2021-05-07 |
沃雅戈治疗公司 |
产生基因治疗制剂的系统和方法
|
US20210163991A1
(en)
|
2018-08-10 |
2021-06-03 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
CA3111076A1
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
WO2020069461A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
JP2022512589A
(ja)
|
2018-10-01 |
2022-02-07 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Gm1ガングリオシドーシスの治療に有用な組成物
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
CN113166731A
(zh)
|
2018-10-05 |
2021-07-23 |
沃雅戈治疗公司 |
编码aav生产蛋白的工程化核酸构建体
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
JP2022514112A
(ja)
|
2018-10-15 |
2022-02-09 |
リジェネクスバイオ インコーポレイテッド |
複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
|
EP3867389A1
(de)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expressionsvektoren zur massenproduktion von raav im baculovirus/sf9-system
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP4269579A3
(de)
|
2019-01-04 |
2024-01-24 |
Ultragenyx Pharmaceutical Inc. |
Gentherapiekonstrukte zur behandlung der wilson-krankheit
|
EP3911410A1
(de)
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Verfahren und systeme zur herstellung von aav-partikeln
|
JP2022523050A
(ja)
*
|
2019-01-23 |
2022-04-21 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり
|
CN113924115A
(zh)
|
2019-01-31 |
2022-01-11 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
KR20210131370A
(ko)
|
2019-02-22 |
2021-11-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
MX2021010149A
(es)
|
2019-02-25 |
2021-09-14 |
Novartis Ag |
Composiciones y metodos para tratar la distrofia cristalina de bietti.
|
KR20210132095A
(ko)
|
2019-02-26 |
2021-11-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
크라베병의 치료에 유용한 조성물
|
SG11202110789VA
(en)
|
2019-04-03 |
2021-10-28 |
Regenxbio Inc |
Gene therapy for eye pathologies
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
WO2020210600A1
(en)
|
2019-04-11 |
2020-10-15 |
Regenxbio Inc. |
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
|
CA3136939A1
(en)
|
2019-04-19 |
2020-10-22 |
Regenxbio Inc. |
Adeno-associated virus vector formulations and methods
|
JP2022530126A
(ja)
*
|
2019-04-23 |
2022-06-27 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用
|
KR20220012231A
(ko)
|
2019-04-24 |
2022-02-03 |
리젠엑스바이오 인크. |
완전-인간 번역 후 변형된 항체 치료제
|
JP2022530845A
(ja)
*
|
2019-04-27 |
2022-07-04 |
オクジェン アイエヌシー. |
眼疾患に対するadeno随伴ウイルス連ウイルスベクター媒介遺伝子治療
|
US20220204990A1
(en)
*
|
2019-04-29 |
2022-06-30 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
AU2020314883A1
(en)
*
|
2019-07-15 |
2022-03-03 |
Meiragtx Uk Ii Limited |
Modified AAV capsid proteins for treatment of arthritic disease
|
CA3145112A1
(en)
|
2019-07-26 |
2021-02-04 |
Chunping Qiao |
Engineered nucleic acid regulatory element and methods of uses thereof
|
US20220396806A1
(en)
|
2019-07-26 |
2022-12-15 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
KR20220051246A
(ko)
|
2019-08-26 |
2022-04-26 |
리젠엑스바이오 인크. |
완전 인간 번역 후 변형된 항-VEGF Fab를 사용한 당뇨병성 망막병증의 치료
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
CN114555814A
(zh)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白-连接子聚合蛋白
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
CN114728049A
(zh)
|
2019-10-07 |
2022-07-08 |
再生生物股份有限公司 |
腺相关病毒载体药物组合物和方法
|
EP4045664A1
(de)
*
|
2019-10-16 |
2022-08-24 |
Wuxi Apptec (Shanghai) Co., Ltd. |
Neue aav-variante
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
EP4065596A2
(de)
|
2019-11-28 |
2022-10-05 |
RegenxBio Inc. |
Mikrodystrophiegentherapiekonstrukte und deren verwendungen
|
KR20220112283A
(ko)
|
2019-12-10 |
2022-08-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
Hunter 질환 치료용 아데노-연합된 바이러스 벡터
|
WO2021119257A1
(en)
*
|
2019-12-10 |
2021-06-17 |
Homology Medicines, Inc. |
Adeno-associated virus compositions and methods of use thereof
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
EP4093428A1
(de)
|
2020-01-22 |
2022-11-30 |
RegenxBio Inc. |
Behandlung von mucopolysaccharidose i mit vollständig menschlicher glykosylierter menschlicher alpha-l-iduronidase (idua)
|
WO2021154963A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
CA3168251A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
EP4096721A1
(de)
|
2020-02-02 |
2022-12-07 |
The Trustees of The University of Pennsylvania |
Zusammensetzungen zur behandlung von gm1-gangliosidose
|
CA3164714A1
(en)
|
2020-02-14 |
2021-08-19 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating cdkl5 deficiency disorder
|
EP4110792A1
(de)
*
|
2020-02-25 |
2023-01-04 |
Children's Medical Research Institute |
Capsid-polypeptide und vektoren von adeno-assoziiertem virus
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
BR112022019047A2
(pt)
|
2020-03-27 |
2022-11-01 |
UCB Biopharma SRL |
Peptídeos de domínio knob autônomos
|
EP4127189A1
(de)
|
2020-03-31 |
2023-02-08 |
Ultragenyx Pharmaceutical Inc. |
Gentherapie zur behandlung von propionischer azidämie
|
JP2023522002A
(ja)
*
|
2020-04-13 |
2023-05-26 |
マサチューセッツ・アイ・アンド・イア・インファーマリー |
コロナウイルスに対するワクチンの作製方法および使用方法
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
US20230304034A1
(en)
|
2020-05-12 |
2023-09-28 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
AU2021271635A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
US20230212606A1
(en)
|
2020-05-13 |
2023-07-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
EP4165195A2
(de)
|
2020-05-13 |
2023-04-19 |
Akouos, Inc. |
Zusammensetzungen und verfahren zur behandlung von slc26a4-assoziiertem hörverlust
|
EP4158037A1
(de)
|
2020-05-26 |
2023-04-05 |
Shape Therapeutics Inc. |
Hochdurchsatz-engineering von funktionellen aav-kapsiden
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
JP2023531451A
(ja)
|
2020-06-17 |
2023-07-24 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
遺伝子療法患者の治療のための組成物及び方法
|
EP4179091A1
(de)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Verfahren und zusammensetzungen zur behandlung von epilepsie
|
EP4179097A1
(de)
|
2020-07-13 |
2023-05-17 |
The Trustees of The University of Pennsylvania |
Zusammensetzungen zur behandlung von morbus charcot-marie-tooth
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
CN115927398A
(zh)
*
|
2020-07-29 |
2023-04-07 |
舒泰神(北京)生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
EP4189077A1
(de)
|
2020-07-30 |
2023-06-07 |
Shape Therapeutics Inc. |
Stabile zelllinien zur induzierbaren herstellung von raav-virionen
|
MX2023002293A
(es)
|
2020-08-24 |
2023-05-19 |
Univ Pennsylvania |
Vectores virales que codifican fusiones de agonistas del receptor de glp-1 y usos de estos en el tratamiento de enfermedades metabólica.
|
BR112023002904A2
(pt)
|
2020-08-26 |
2023-04-25 |
Univ Pennsylvania |
Vírus adenoassociado recombinante para tratar neurodegeneração com início na idade adulta associada a grn
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
WO2022076595A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
WO2022076549A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
JP2023544799A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
凝集体形成物を含む製剤などの脈絡膜上投与用の製剤
|
IL301643A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Gene therapy for ocular manifestations of CLN2 disease
|
EP4225777A2
(de)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Adeno-assoziierte viren zur okularen verabreichung einer gentherapie
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
US20230365955A1
(en)
|
2020-10-09 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
IL302127A
(en)
|
2020-10-18 |
2023-06-01 |
Univ Pennsylvania |
An improved adeno-associated virus (AAV) vector and its uses
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
IL302282A
(en)
|
2020-10-29 |
2023-06-01 |
Regenxbio Inc |
Vectored TNF-alpha antagonists for ocular indications
|
EP4236974A2
(de)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vektorisierte faktor xii-antikörper und verabreichung davon
|
US20240024507A1
(en)
|
2020-12-01 |
2024-01-25 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
JP2023551911A
(ja)
|
2020-12-01 |
2023-12-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アンジェルマン症候群の治療のための組成物及びその使用
|
AU2021391433A1
(en)
|
2020-12-01 |
2023-06-22 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
CA3201743A1
(en)
|
2020-12-16 |
2022-06-23 |
Robert STADELMAN |
Method of producing a recombinant adeno-associated virus particle
|
CA3203373A1
(en)
|
2020-12-29 |
2022-07-07 |
Emmanuel John Simons |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
US20240084329A1
(en)
|
2021-01-21 |
2024-03-14 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
WO2022169774A1
(en)
|
2021-02-02 |
2022-08-11 |
University Of Massachusetts |
Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
|
AU2022221284A1
(en)
|
2021-02-10 |
2023-08-17 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
EP4298227A1
(de)
|
2021-02-26 |
2024-01-03 |
Takeda Pharmaceutical Company Limited |
Zusammensetzung und verfahren zur behandlung von morbus fabry
|
EP4323520A1
(de)
|
2021-04-12 |
2024-02-21 |
The Trustees of The University of Pennsylvania |
Zusammensetzungen zur behandlung von spinaler und bulbusarer muskelatrophie (sbma)
|
WO2022226296A2
(en)
|
2021-04-23 |
2022-10-27 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
EP4334334A1
(de)
|
2021-04-23 |
2024-03-13 |
The Trustees of The University of Pennsylvania |
Neue zusammensetzungen mit hirnspezifischen zielmotiven und zusammensetzungen damit
|
JP2024517143A
(ja)
|
2021-04-26 |
2024-04-19 |
リジェネックスバイオ インコーポレイテッド |
ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与
|
EP4334454A2
(de)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Neue aav-vektoren sowie verfahren und verwendungen davon
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
AU2022299552A1
(en)
|
2021-06-25 |
2024-01-04 |
Oxford Biomedica (Us) Llc |
Adeno-associated virus packaging systems
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
EP4373947A1
(de)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1-kombinationstherapien zur behandlung von muskeldegenerativen erkrankungen
|
WO2023019168A1
(en)
|
2021-08-11 |
2023-02-16 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating a muscular dystrophy
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
EP4384598A1
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung komplementvermittelter entzündungsreaktionen
|
EP4384193A2
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung von durch instant-blut vermittelten entzündungsreaktionen
|
WO2023028513A1
(en)
|
2021-08-24 |
2023-03-02 |
Oxford Biomedica Solutions Llc |
Adeno-associated virus formulations
|
WO2023028567A2
(en)
*
|
2021-08-25 |
2023-03-02 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease
|
AU2022356427A1
(en)
|
2021-09-30 |
2024-05-09 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
US20230183658A1
(en)
|
2021-10-29 |
2023-06-15 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the purification of adeno-associated virus
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023102078A2
(en)
|
2021-12-01 |
2023-06-08 |
Shape Therapeutics Inc. |
Functional aav capsids for intravitreal administration
|
WO2023102079A1
(en)
|
2021-12-01 |
2023-06-08 |
Shape Therapeutics Inc. |
Functional aav capsids for systemic administration
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023106256A1
(ja)
*
|
2021-12-06 |
2023-06-15 |
学校法人順天堂 |
改変型アデノ随伴ウイルスベクター
|
US20230323395A1
(en)
|
2021-12-15 |
2023-10-12 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
TW202338086A
(zh)
|
2022-01-10 |
2023-10-01 |
賓州大學委員會 |
有用於治療異染性白質失養症之組成物
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
AR128422A1
(es)
|
2022-02-02 |
2024-05-08 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023172491A1
(en)
|
2022-03-07 |
2023-09-14 |
Ultragenyx Pharmaceutical Inc. |
Modified batch aav production systems and methods
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
CN115960177B
(zh)
*
|
2022-10-09 |
2023-07-07 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
CN115838399B
(zh)
*
|
2022-12-08 |
2023-08-11 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|